(SDAX, Technology, SMHN GR)



Hold EUR 60.00	(EUR 56.50)	Value Indicators: DCF: FCF-Value Potential 26e:	60.00	Warburg ESG Risk Score: ESG Score (MSCI based): Balance Sheet Score: Market Liquidity Score:	3.8 4.0 5.0 2.5	Leading solution provider for niche markets advanced packaging, 3D			
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2024e		
		Market cap:	1,237.7	Freefloat	100.00 %	Beta:	1.3		
Price	EUR 64.80	No. of shares (m):	19.1	Kempen	10.00 %	Price / Book:	4.8 x		
Downside	-7.4 %	EV:	1,114.6	Teslin	7.50 %	Equity Ratio:	59 %		
		Freefloat MC:	1,237.7	Henderson	5.00 %				
		Ø Trad. Vol. (30d):	5.57 m	JP Morgan	3.20 %				

### Preview Q2: Guidance-hike very likely

Expected Figu	ures Q	2/2024:				
FY End: 31.12. in EUR m	Q2 24e	Q2 23	yoy	6M 24e	6M 23	yoy
Order entry Sales	92.0 87.0	83.4 68.3	10 % 27 %	190.3 180.5	178.2 132.4	7 % 36 %
EBIT	<b>11.4</b> 13.1 %	-0.3 -0.4 %	n.a.	<b>26.2</b> 14.5 %	11.5 8.7 %	128 %


SUSS has scheduled to release its Q2 results in early August, but we deem it **highly likely that the company will raise its FY 2024 guidance before the official reporting**. SUSS provided guidance for a 10-12% EBIT margin early in the year, which was already regarded to be too cautious but had its roots in the disappointingly weak profitability in Q3 2023, when the new CEO had to issue a profit warning just weeks after his arrival. Strong Q1 profitability with a gross margin of 39% and an EBIT margin of 16% came as a positive surprise in May.

Product mix should support a continuation of the positive gross-margin development in 2024. Temporary bonders are expected to be one of the strongest-margin products at the moment as customers rushed to placed orders in light of the surging HBM demand. As the ramp-up at the Taiwanese production site only commenced in early 2024, contributions from temporary bonders have not been strong in Q1 and are expected to increase sequentially once full capacity is reached (at least EUR 150m annualized) in mid-Q3. As the high Q1 gross margin did not benefit from special effects, the ramp in Taiwan is proceeding as planned and if SUSS is able to avoid hiccups, which burdened profitability more than once in the past few years, gross margins might well remain above the guidance range (35–38%) reflecting the positive mix effects. We are incorporating a gross margin at the high end of the range, which leaves some scope.

While revenues are largely capacity constrained, the top-line estimates are slightly increased on the assumption that SUSS is able to squeeze in a few additional temporary bonders owing to a smooth ramp-up in Taiwan and sound customer demand. With this, SUSS is now expected to achieve an EBIT margin of ~14% (with additional upside if revenues reach higher levels or gross margins are ahead of forecasts). In light of this, a guidance-hike appears very likely. Owing to past disappointments though, SUSS might increase its targets in more than one step.

The **PT** is being raised to **EUR 60** against the background of higher estimates. While our HBM-model indicates roughly stable demand at high levels for temporary bonders in the near term, accelerated capacity extensions might nevertheless still lead to additional upside for 2025.

Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2024e (old)	+/-	2025e (old)	+/-	2026e (old)	+/-	<ul> <li>Slight increase in top-line assumptions, driven by buoyant demand for temporary bonders</li> </ul>
Sales	370.0	2.7 %	445.0	2.2 %	485.1	3.2 %	<ul> <li>EBIT margin expected to exceed the 15%-mark from 2025 onwards</li> </ul>
EBIT	48.1	10.5 %	69.1	6.0 %	80.7	7.5 %	




Rel. Performance vs SDAX:	
1 month:	9.5 %
6 months:	139.1 %
Year to date:	131.5 %
Trailing 12 months:	169.0 %
Company events:	
07.08.24	Q2

FY End: 31.12.	CAGR										
in EUR m	(23-26e)	2020	2021	2022	2023	2024e	2025e	2026e			
Sales	18.0 %	252.1	263.4	299.1	304.3	380.0	455.0	500.5			
Change Sales yoy		17.9 %	4.5 %	13.6 %	1.7 %	24.9 %	19.7 %	10.0 %			
Gross profit margin		33.2 %	35.8 %	36.8 %	34.1 %	38.0 %	38.3 %	39.0 %			
EBITDA	39.8 %	28.2	29.6	41.9	34.7	60.5	80.9	94.6			
Margin		11.2 %	11.2 %	14.0 %	11.4 %	15.9 %	17.8 %	18.9 %			
EBIT		20.4	22.6	32.8	27.8	53.2	73.3	86.7			
Margin		8.1 %	8.6 %	11.0 %	9.1 %	14.0 %	16.1 %	17.3 %			
Net income	134.6 %	12.3	16.0	24.5	4.7	96.4	52.1	61.1			
EPS	133.9 %	0.65	0.84	1.28	0.25	5.04	2.72	3.20			
EPS adj.	52.1 %	0.78	0.84	1.28	0.91	2.01	2.72	3.20			
DPS	31.0 %	0.00	0.16	0.20	0.20	0.30	0.40	0.45			
Dividend Yield		n.a.	0.7 %	1.3 %	0.9 %	0.5 %	0.6 %	0.7 %			
FCFPS		2.47	0.77	0.84	0.41	1.34	1.41	2.31			
FCF / Market cap		19.2 %	3.2 %	5.6 %	1.8 %	2.1 %	2.2 %	3.6 %			
EV / Sales		0.9 x	1.6 x	0.8 x	1.3 x	2.9 x	2.4 x	2.1 x			
EV / EBITDA		8.2 x	14.5 x	6.0 x	11.5 x	18.4 x	13.5 x	11.2 x			
EV / EBIT		11.4 x	19.1 x	7.6 x	14.3 x	21.0 x	14.9 x	12.2 x			
P/E		19.8 x	28.6 x	11.7 x	89.7 x	12.9 x	23.8 x	20.3 x			
P / E adj.	-6.3 %	16.5 x	28.6 x	11.7 x	24.6 x	32.2 x	23.8 x	20.3 x			
FCF Potential Yield		7.7 %	5.4 %	12.4 %	2.0 %	3.6 %	4.9 %	6.1 %			
Net Debt		-13.9	-28.4	-36.3	-31.2	-123.1	-144.3	-180.7			
ROCE (NOPAT)		9.3 %	13.0 %	18.3 %	11.9 %	26.6 %	34.5 %	35.8 %			
Guidance: 2	2024: Sales: 340 - 370m; EBIT 10-12%										

07.11.24

Q3






## **Company Background**

- Globally leading manufacturer of systems for the MEMS, advanced packaging, 3D IC and LED niche markets with the product segments lithography (mask aligner,coater), bonder and equipment to clean photomasks.
- MEMS integrate electronic and mechanical components.
- Advanced packaging is a special packaging process used as an alternative to the classic wire bonding ("flip chip") for semiconductors where these are directly bonded to the substrate without wire connections.
- 3D packaging is a solution to the increasingly difficult ongoing structural downsizing of semiconductors, which is e.g. used in Al related ICs. This market offers enormous growth potential for SÜSS.
- The majority of production is located at three sites (Garching, Sternenfels, Taiwan) which offer ample capacity for anticipated growth. SÜSS has ca. 1100 employees.

### **Competitive Quality**

- SÜSS consistently focuses on the core topics (precision, reliability and low total cost of ownership) in all segments and gears the products to the customers' needs.
- The 75-year company history and the consistently high product quality have firmly established SÜSS as a brand-name in the addressed markets.
- This and the global service network make the company a preferred supplier for production equipment in particular.
- As the respective markets have a niche character, SÜSS usually only has to face moderate competition and rarely has to compete with the major suppliers of the sector.
- This combined with the high product complexity poses a major barrier to market entry and secures the company a leading position in the respective markets.





DCF model														
	Detaile	d forecas	t period				٦	Γransition	al period					Term. Value
Figures in EUR m	2024e	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	
Sales	380.0	455.0	500.5	555.6	616.7	684.5	752.9	790.6	830.1	863.3	897.9	915.8	934.1	
Sales change	24.9 %	19.7 %	10.0 %	11.0 %	11.0 %	11.0 %	10.0 %	5.0 %	5.0 %	4.0 %	4.0 %	2.0 %	2.0 %	2.0 %
EBIT	53.2	73.3	86.7	100.0	111.0	123.2	139.3	146.3	153.6	159.7	166.1	169.4	172.8	
EBIT-margin	14.0 %	16.1 %	17.3 %	18.0 %	18.0 %	18.0 %	18.5 %	18.5 %	18.5 %	18.5 %	18.5 %	18.5 %	18.5 %	
Tax rate (EBT)	30.2 %	29.7 %	29.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	28.5 %	
NOPAT	37.1	51.5	61.1	71.5	79.4	88.1	99.6	104.6	109.8	114.2	118.8	121.1	123.6	
Depreciation	7.3	7.6	7.9	10.8	12.3	13.7	15.1	15.8	16.6	17.3	18.0	18.3	18.7	
in % of Sales	1.9 %	1.7 %	1.6 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	2.0 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	8.0	14.8	13.9	13.4	17.1	19.0	19.2	10.5	11.1	9.3	9.7	5.0	5.1	
- Capex	12.0	18.0	11.0	22.8	14.2	15.1	15.8	16.6	17.4	18.1	18.9	19.2	19.6	
Capex in % of Sales	3.2 %	4.0 %	2.2 %	2.3 %	2.3 %	2.2 %	2.1 %	2.1 %	2.1 %	2.1 %	2.1 %	2.1 %	2.1 %	
- Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	24.4	26.3	44.1	46.2	60.4	67.7	79.7	93.2	97.9	104.0	108.2	115.2	117.5	120
PV of FCF	24.4	24.0	36.8	35.2	42.0	43.0	46.2	49.3	47.3	45.9	43.6	42.4	39.4	535
share of PVs		8.08 %						41.19	9 %					50.73 %

Model parameter				Valuation (m)				
Derivation of WACC:		Derivation of Beta:		Present values 2036e	519			
				Terminal Value	535			
Debt ratio	1.50 %	Financial Strength	1.10	Financial liabilities	15			
Cost of debt (after tax)	2.9 %	Liquidity (share)	1.30	Pension liabilities	2			
Market return	8.25 %	Cyclicality	1.40	Hybrid capital	0			
Risk free rate	2.75 %	Transparency	1.05	Minority interest	0			
		Others	1.40	Market val. of investments	0			
				Liquidity	107	No. of shares (m)	19.1	
WACC	9.52 %	Beta	1.25	Equity Value	1,144	Value per share (EUR)	59.91	

Sens	itivity Va	lue per Sh	are (EUR	)													
		Terminal (	Growth								Delta EBIT	Γ-margin					
Beta	WACC	1.25 %	1.50 %	1.75 %	2.00 %	2.25 %	2.50 %	2.75 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.43	10.5 %	50.73	51.30	51.89	52.53	53.20	53.91	54.66	1.43	10.5 %	47.91	49.45	50.99	52.53	54.07	55.61	57.15
1.34	10.0 %	53.85	54.52	55.23	55.98	56.78	57.63	58.54	1.34	10.0 %	51.06	52.70	54.34	55.98	57.62	59.26	60.90
1.30	9.8 %	55.56	56.29	57.06	57.88	58.76	59.69	60.69	1.30	9.8 %	52.79	54.49	56.18	57.88	59.58	61.27	62.97
1.25	9.5 %	57.37	58.17	59.01	59.91	60.87	61.90	63.01	1.25	9.5 %	54.65	56.40	58.16	59.91	61.66	63.42	65.17
1.20	9.3 %	59.30	60.17	61.10	62.09	63.14	64.28	65.51	1.20	9.3 %	56.63	58.45	60.27	62.09	63.90	65.72	67.54
1.16	9.0 %	61.36	62.31	63.33	64.42	65.59	66.85	68.21	1.16	9.0 %	58.76	60.65	62.53	64.42	66.31	68.19	70.08
1.07	8.5 %	65.93	67.08	68.31	69.64	71.08	72.63	74.33	1.07	8.5 %	63.53	65.57	67.61	69.64	71.68	73.72	75.75

- Growth estimates mirror 10% CAGR past 2025
- Sustainable EBIT margin of 18.5% anticipated



### Free Cash Flow Value Potential

Warburg Research's valuation tool "FCF Value Potential" reflects the ability of the company to generate sustainable free cash flows. It is based on the "FCF potential" - a FCF "ex growth" figure - which assumes unchanged working capital and pure maintenance capex. A value indication is derived via the perpetuity of a given year's "FCF potential" with consideration of the weighted costs of capital. The fluctuating value indications over time add a timing element to the DCF model (our preferred valuation tool).

in EUR m	202	20	2021	2022	2023	2024e	2025e	2026e
Net Income before minorities	12	.3	16.0	24.5	4.7	96.4	52.1	61.1
+ Depreciation + Amortisation	7	.8	7.1	9.1	6.9	7.3	7.6	7.9
- Net Interest Income	-0	.4	-0.5	-0.3	0.5	1.3	0.6	0.0
- Maintenance Capex	2	.7	2.8	2.9	3.0	4.0	5.0	5.0
+ Other	0	.0	2.6	0.0	0.0	-58.0	0.0	0.0
= Free Cash Flow Potential	17	.8	23.3	31.0	8.1	40.4	54.1	64.0
FCF Potential Yield (on market EV)	7.7	%	5.4 %	12.4 %	2.0 %	3.6 %	4.9 %	6.1 %
WACC	9.52	%	9.52 %	9.52 %	9.52 %	9.52 %	9.52 %	9.52 %
= Enterprise Value (EV)	232	.3	430.1	249.4	397.2	1,115.6	1,094.4	1,057.9
= Fair Enterprise Value	187	.1	244.9	325.7	84.7	424.4	567.8	672.2
- Net Debt (Cash)	-32	.8	-32.8	-32.8	-32.8	-124.7	-145.9	-182.3
- Pension Liabilities	1	.6	1.6	1.6	1.6	1.6	1.6	1.6
- Other	0	.0	0.0	0.0	0.0	0.0	0.0	0.0
<ul> <li>Market value of minorities</li> </ul>	0	.0	0.0	0.0	0.0	0.0	0.0	0.0
+ Market value of investments	0	.0	0.0	0.0	0.0	0.0	0.0	0.0
= Fair Market Capitalisation	218	.3	276.1	356.9	115.9	547.6	712.1	853.0
Number of shares, average	19	.1	19.1	19.1	19.1	19.1	19.1	19.1
= Fair value per share (EUR)	11.4	<b>42</b>	14.45	18.67	6.06	28.65	37.25	44.62
premium (-) / discount (+) in %						-55.8 %	-42.5 %	-31.1 %
Sensitivity Fair value per Share (El	UR)							
12	2.52 % 9.0	08	11.39	14.60	5.01	23.35	30.16	36.23
<b>1</b> 1	1.52 % 9.	73	12.23	15.73	5.30	24.81	32.12	38.55
10	).52 % 10.5	50	13.24	17.07	5.65	26.56	34.46	41.31
	9.52 % 11.4		14.45	18.67	6.06	28.65	37.25	44.62
	3.52 % 12.5		15.96	20.69	6.59	31.28	40.77	48.79
	7.52 % 14.0		17.87	23.22	7.25	34.58	45.18	54.01
6	6.52 % 15.9	94	20.35	26.53	8.11	38.89	50.95	60.84

Increasing sales and margins result in higher value indications in coming years

# **SUSS MicroTec**




Valuation							
	2020	2021	2022	2023	2024e	2025e	2026e
Price / Book	1.8 x	2.9 x	1.6 x	2.4 x	4.8 x	4.0 x	3.4 x
Book value per share ex intangibles	5.92	6.95	8.01	7.98	12.35	14.78	17.57
EV / Sales	0.9 x	1.6 x	0.8 x	1.3 x	2.9 x	2.4 x	2.1 x
EV / EBITDA	8.2 x	14.5 x	6.0 x	11.5 x	18.4 x	13.5 x	11.2 x
EV / EBIT	11.4 x	19.1 x	7.6 x	14.3 x	21.0 x	14.9 x	12.2 x
EV / EBIT adj.*	10.1 x	19.1 x	8.3 x	14.3 x	21.0 x	14.9 x	12.2 x
P / FCF	5.2 x	31.2 x	17.8 x	54.1 x	48.2 x	46.1 x	28.1 x
P/E	19.8 x	28.6 x	11.7 x	89.7 x	12.9 x	23.8 x	20.3 x
P / E adj.*	16.5 x	28.6 x	11.7 x	24.6 x	32.2 x	23.8 x	20.3 x
Dividend Yield	n.a.	0.7 %	1.3 %	0.9 %	0.5 %	0.6 %	0.7 %
FCF Potential Yield (on market EV)	7.7 %	5.4 %	12.4 %	2.0 %	3.6 %	4.9 %	6.1 %
*Adjustments made for: -							
Company Specific Items							
	2020	2021	2022	2023	2024e	2025e	2026e
Order entry	281.1	335.6	410.9	420.5	465.0	0.0	0.0
Order backlog	120.1	193.3	346.4	452.5	0.0	0.0	0.0



Consolidated profit and loss							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026
Sales	252.1	263.4	299.1	304.3	380.0	455.0	500.5
Change Sales yoy	17.9 %	4.5 %	13.6 %	1.7 %	24.9 %	19.7 %	10.0 %
COGS	168.4	169.2	189.1	200.4	235.6	280.7	305.3
Gross profit	83.7	94.2	110.1	103.9	144.4	174.3	195.2
Gross margin	33.2 %	35.8 %	36.8 %	34.1 %	38.0 %	38.3 %	39.0 %
Research and development	19.8	22.1	25.0	31.3	37.5	41.0	44.0
Sales and marketing	23.5	24.9	28.5	21.4	24.5	27.0	29.5
Administration expenses	20.8	22.9	23.3	24.2	28.0	30.5	32.5
Other operating expenses	3.4	5.9	12.2	6.5	2.3	2.5	2.5
Other operating income	4.3	4.2	11.8	7.3	1.1	0.0	0.0
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	28.2	29.6	41.9	34.7	60.5	80.9	94.6
Margin	11.2 %	11.2 %	14.0 %	11.4 %	15.9 %	17.8 %	18.9 %
Depreciation of fixed assets	7.1	6.4	8.1	5.3	6.3	6.6	6.9
EBITA	21.1	23.2	33.8	29.3	54.2	74.3	87.7
Amortisation of intangible assets	0.7	0.7	1.0	1.5	1.0	1.0	1.0
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	20.4	22.6	32.8	27.8	53.2	73.3	86.7
Margin	8.1 %	8.6 %	11.0 %	9.1 %	14.0 %	16.1 %	17.3 %
EBIT adj.	23.0	22.6	30.0	27.8	53.2	73.3	86.7
Interest income	0.0	0.0	0.3	1.0	1.5	0.8	0.2
Interest expenses	0.4	0.5	0.6	0.4	0.2	0.2	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	20.0	22.1	32.5	28.3	54.5	73.9	86.7
Margin	7.9 %	8.4 %	10.9 %	9.3 %	14.3 %	16.2 %	17.3 %
Total taxes	7.7	6.1	8.0	11.0	16.1	21.8	25.6
Net income from continuing operations	12.3	16.0	24.5	17.3	38.4	52.1	61.1
Income from discontinued operations (net of tax)	0.0	0.0	0.0	-12.6	58.0	0.0	0.0
Net income before minorities	12.3	16.0	24.5	4.7	96.4	52.1	61.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	12.3	16.0	24.5	4.7	96.4	52.1	61.1
Margin	4.9 %	6.1 %	8.2 %	1.6 %	25.4 %	11.4 %	12.2 %
Number of shares, average	19.1	19.1	19.1	19.1	19.1	19.1	19.1
EPS	0.65	0.84	1.28	0.25	5.04	2.72	3.20
EPS adj.	0.78	0.84	1.28	0.91	2.01	2.72	3.20
*Adjustments made for:							

Guidance: 2024: Sales: 340 - 370m; EBIT 10-12%

Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Total Operating Costs / Sales	25.1 %	27.2 %	25.8 %	25.0 %	24.0 %	22.2 %	21.7 %
Operating Leverage	n.a.	2.3 x	3.4 x	-8.9 x	3.7 x	1.9 x	1.8 x
EBITDA / Interest expenses	66.6 x	63.5 x	74.2 x	82.9 x	302.5 x	404.3 x	473.0 x
Tax rate (EBT)	38.3 %	27.5 %	24.6 %	38.8 %	29.5 %	29.5 %	29.5 %
Dividend Payout Ratio	0.0 %	19.1 %	15.6 %	22.1 %	14.9 %	14.7 %	14.1 %
Sales per Employee	263,139	237,760	248,246	252,081	304,000	694,656	764,122




Source: Warburg Research



Consolidated balance sheet							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026
Assets							
Goodwill and other intangible assets	23.4	24.0	24.6	24.1	24.1	24.1	24.1
thereof other intangible assets	5.0	5.6	5.9	5.5	5.5	5.5	5.5
thereof Goodwill	18.3	18.4	18.6	18.5	18.5	18.5	18.5
Property, plant and equipment	40.4	44.5	48.9	31.1	35.8	46.2	49.3
Financial assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	63.7	68.5	73.4	55.2	59.9	70.3	73.4
Inventories	73.0	99.5	150.5	166.7	165.2	168.5	166.8
Accounts receivable	48.0	47.4	57.0	52.9	64.5	76.0	82.3
Liquid assets	40.8	52.1	61.3	48.0	138.9	160.0	196.5
Other short-term assets	5.9	11.6	11.0	46.9	12.9	12.9	12.9
Current assets	167.7	210.7	279.8	314.5	381.4	417.4	458.5
Total Assets	231.4	279.2	353.3	369.7	441.4	487.7	531.9
Liabilities and shareholders' equity							
Subscribed capital	19.1	19.1	19.1	19.1	19.1	19.1	19.1
Capital reserve	119.0	135.0	156.5	157.3	157.3	157.3	157.3
Retained earnings	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other equity components	-1.6	2.8	2.2	0.2	83.8	130.1	183.6
Shareholders' equity	136.5	156.9	177.7	176.6	260.2	306.6	360.0
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	136.5	156.9	177.7	176.6	260.2	306.6	360.0
Provisions	10.9	11.2	11.8	10.6	10.6	10.6	10.6
thereof provisions for pensions and similar obligations	6.4	5.3	5.0	1.6	1.6	1.6	1.6
Financial liabilities (total)	20.5	18.3	20.0	15.2	14.2	14.2	14.2
Short-term financial liabilities	1.4	1.2	1.2	1.2	1.2	1.2	1.2
Accounts payable	9.8	24.4	27.1	27.1	31.2	31.2	21.9
Other liabilities	53.7	68.4	116.7	140.2	125.2	125.2	125.2
Liabilities	94.9	122.3	175.5	193.1	181.2	181.2	171.9
Total liabilities and shareholders' equity	231.4	279.2	353.3	369.7	441.4	487.7	531.9


Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Efficiency of Capital Employment							
Operating Assets Turnover	2.0 x	2.0 x	2.0 x	2.2 x	2.5 x	2.6 x	2.6 x
Capital Employed Turnover	2.1 x	2.1 x	2.1 x	2.1 x	2.8 x	2.8 x	2.8 x
ROA	19.4 %	23.4 %	33.4 %	8.6 %	160.9 %	74.0 %	83.2 %
Return on Capital							
ROCE (NOPAT)	9.3 %	13.0 %	18.3 %	11.9 %	26.6 %	34.5 %	35.8 %
ROE	9.4 %	10.9 %	14.7 %	2.7 %	44.1 %	18.4 %	18.3 %
Adj. ROE	11.4 %	10.9 %	14.7 %	9.8 %	17.6 %	18.4 %	18.3 %
Balance sheet quality							
Net Debt	-13.9	-28.4	-36.3	-31.2	-123.1	-144.3	-180.7
Net Financial Debt	-20.3	-33.8	-41.3	-32.8	-124.7	-145.9	-182.3
Net Gearing	-10.2 %	-18.1 %	-20.4 %	-17.7 %	-47.3 %	-47.1 %	-50.2 %
Net Fin. Debt / EBITDA	n.a.						
Book Value / Share	7.1	8.2	9.3	9.2	13.6	16.0	18.8
Book value per share ex intangibles	5.9	7.0	8.0	8.0	12.4	14.8	17.6





Consolidated cash flow statement							
In EUR m	2020	2021	2022	2023	2024e	2025e	2026e
Net income	12.3	16.0	24.5	4.7	96.4	52.1	61.1
Depreciation of fixed assets	7.1	6.4	8.1	5.3	6.3	6.6	6.9
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	0.7	0.7	1.0	1.5	1.0	1.0	1.0
Increase/decrease in long-term provisions	0.4	-1.2	-0.5	-0.1	0.0	0.0	0.0
Other non-cash income and expenses	9.1	7.8	8.2	19.0	-58.0	0.0	0.0
Cash Flow before NWC change	29.5	29.7	41.3	30.5	45.7	59.7	69.0
Increase / decrease in inventory	9.8	-29.5	-52.8	-29.4	1.5	-3.3	1.7
Increase / decrease in accounts receivable	2.1	1.9	-11.1	0.2	-11.6	-11.5	-6.3
Increase / decrease in accounts payable	13.7	22.3	46.5	11.2	2.1	0.0	-9.3
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	25.6	-5.4	-17.4	-18.0	-8.0	-14.8	-13.9
Net cash provided by operating activities [1]	55.1	24.3	23.9	12.5	37.7	44.9	55.1
Investments in intangible assets	1.1	1.2	1.1	1.1	1.0	1.0	1.0
Investments in property, plant and equipment	8.0	8.5	10.5	10.5	11.0	17.0	10.0
Payments for acquisitions	-3.3	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.1	0.0	0.0	0.0	70.0	0.0	0.0
Net cash provided by investing activities [2]	-11.2	-9.6	-7.9	-4.6	58.0	-18.0	-11.0
Change in financial liabilities	-13.3	-3.8	-3.7	-3.4	-1.0	0.0	0.0
Dividends paid	0.0	0.0	-3.1	-3.8	-3.8	-5.7	-7.6
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	-13.3	-3.8	-6.8	-7.2	-4.8	-5.7	-7.6
Change in liquid funds [1]+[2]+[3]	30.7	10.9	9.3	0.7	90.9	21.1	36.5
Effects of exchange-rate changes on cash	-0.2	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	40.8	51.7	61.3	52.0	129.0	150.1	186.6

Financial Ratios							
	2020	2021	2022	2023	2024e	2025e	2026e
Cash Flow							
FCF	47.2	14.7	16.0	7.9	25.7	26.9	44.1
Free Cash Flow / Sales	18.7 %	5.6 %	5.4 %	2.6 %	6.8 %	5.9 %	8.8 %
Free Cash Flow Potential	17.8	23.3	31.0	8.1	40.4	54.1	64.0
Free Cash Flow / Net Profit	382.4 %	91.9 %	65.4 %	167.2 %	26.7 %	51.6 %	72.2 %
Interest Received / Avg. Cash	0.0 %	0.0 %	0.5 %	1.7 %	1.6 %	0.5 %	0.1 %
Interest Paid / Avg. Debt	1.7 %	2.4 %	2.9 %	2.4 %	1.4 %	1.4 %	1.4 %
Management of Funds							
Investment ratio	3.6 %	3.7 %	3.9 %	3.8 %	3.2 %	4.0 %	2.2 %
Maint. Capex / Sales	1.1 %	1.1 %	1.0 %	1.0 %	1.1 %	1.1 %	1.0 %
Capex / Dep	117.1 %	136.4 %	127.6 %	169.0 %	164.4 %	236.8 %	139.2 %
Avg. Working Capital / Sales	37.9 %	33.0 %	32.0 %	34.2 %	28.8 %	26.6 %	27.0 %
Trade Debtors / Trade Creditors	487.7 %	194.0 %	210.3 %	195.2 %	206.7 %	243.6 %	375.8 %
Inventory Turnover	2.3 x	1.7 x	1.3 x	1.2 x	1.4 x	1.7 x	1.8 x
Receivables collection period (days)	69	66	70	63	62	61	60
Payables payment period (days)	21	53	52	49	48	41	26
Cash conversion cycle (Days)	151	155	157	159	138	129	132





### **LEGAL DISCLAIMER**

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

#### **COPYRIGHT NOTICE**

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

# DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also <a href="http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation">http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation</a>). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

### SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

The Warburg ESG Risk Score is based on information © 2020 MSCI ESG Research LLC. Reproduced by permission. Although Warburg Research's information providers, including without limitation, MSCI ESG Research LLC and its affiliates (the "ESG Parties"), obtain information (the "Information") from sources they consider reliable, none of the ESG Parties warrants or guarantees the originality, accuracy and/or completeness, of any data herein and expressly disclaim all express or implied warranties, including those of merchantability and fitness for a particular purpose. The Information may only be used for your internal use, may not be reproduced or redisseminated in any form and may not be used as a basis for, or a component, of any financial instruments or products indices. Further, none of the Information can in and of itself be used to determine which securities to buy or sell or when to buy or sell them. None of the ESG Parties shall have any liability for any errors or omissions in connection with any data herein, or any liability for any direct, indirect, special, punitive, consequential or any other damage (including lost profits) even if notified of the possibility.



#### Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M. Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

# Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- -1- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold a **share of more than 5**% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the **management of a consortium** for an issue in the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research **manage financial instruments**, which are, or the issuers of which are, subject of the investment recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide **investment banking and/or**investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation provided that this disclosure does not result in the disclosure of confidential business information.
- -5- The company compiling the analysis or an affiliated company had reached an **agreement on the compilation of the investment recommendation** with the analysed company.
- -6a- Warburg Research, or an affiliated company, holds a **net long position of more than 0.5%** of the total issued share capital of the analysed company.
- -6b- Warburg Research, or an affiliated company, holds a **net short position of more than 0.5%** of the total issued share capital of the analysed company.
- -6c- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company.
- -7- The company preparing the analysis as well as its affiliated companies and employees have **other important interests** in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months			
SUSS MicroTec	5	https://www.mmwarburg.com/disclaimer/disclaimer en/DE000A1K0235.htm			



### INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

<u>"_"</u>	Rating suspended:	The available information currently does not permit an evaluation of the company.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.

WARBURG RESEARCH GMBH - A	ANAI YSFD RESEARCH	UNIVERSE BY RATING
---------------------------	--------------------	--------------------


Rating	Number of stocks	% of Universe
Buy	142	71
Hold	43	21
Sell	10	5
Rating suspended	6	3
Total	201	100

### WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	43	78
Hold	9	16
Sell	1	2
Rating suspended	2	4
Total	55	100

### PRICE AND RATING HISTORY SUSS MICROTEC AS OF 09.07.2024



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Michael Heider Head of Research	+49 40 309537-280 mheider@warburg-research.com	Hannes Müller Software, IT	+49 40 309537-255 hmueller@warburg-research.com
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Andreas Pläsier Banks, Financial Services	+49 40 309537-246 aplaesier@warburg-research.com
Stefan Augustin	+49 40 309537-168	Malte Schaumann	+49 40 309537-170
Cap. Goods, Engineering	saugustin@warburg-research.com	Technology	mschaumann@warburg-research.com
Jan Bauer Renewables	+49 40 309537-155 jbauer@warburg-research.com	Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com
Christian Cohrs	+49 40 309537-175	Simon Stippig	+49 40 309537-265
Industrials & Transportation	ccohrs@warburg-research.com	Real Estate, Telco	sstippig@warburg-research.com
Dr. Christian Ehmann BioTech, Life Science	+49 40 309537-167 cehmann@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Felix Ellmann	+49 40 309537-120	Robert-Jan van der Horst	+49 40 309537-290
Software, IT	fellmann@warburg-research.com	Technology	rvanderhorst@warburg-research.com
<b>Jörg Philipp Frey</b> Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com	Andreas Wolf Software, IT	+49 40 309537-140 awolf@warburg-research.com
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com		
Fabio Hölscher	+49 40 309537-240		
Automobiles, Car Suppliers	fhoelscher@warburg-research.com		
Philipp Kaiser Real Estate, Construction	+49 40 309537-260 pkaiser@warburg-research.com		
Thilo Kleibauer	+49 40 309537-257		
Retail, Consumer Goods	tkleibauer@warburg-research.com		
INSTITUTIONAL EQU			
Klaus Schilling Head of Equity Sales, Germany	+49 69 5050-7400 kschilling@mmwarburg.com	Rudolf Alexander Michaelis Germany	+49 40 3282-2649 rmichaelis@mmwarburg.com
Tim Beckmann	+49 40 3282-2665	Roman Alexander Niklas	+49 69 5050-7412
United Kingdom	tbeckmann@mmwarburg.com	Switzerland	rniklas@mmwarburg.com
Lea Bogdanova United Kingdom, Ireland	+49 69 5050-7411 lbogdanova@mmwarburg.com		
Jens Buchmüller	+49 69 5050-7415	Antonia Möller	+49 69 5050-7417
Scandinavia, Austria	jbuchmueller@mmwarburg.com	Roadshow/Marketing	amoeller@mmwarburg.com
Matthias Fritsch United Kingdom	+49 40 3282-2696 mfritsch@mmwarburg.com	Charlotte Wernicke Roadshow/Marketing	+49 40 3282-2669 cwernicke@mmwarburg.com
Maximilian Martin	+49 69 5050-7413	Juliane Niemann	+49 40 3282-2694
Austria, Poland	mmartin@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSOR	ING
Oliver Merckel	+49 40 3282-2634	Marcel Magiera	+49 40 3282-2662
Head of Sales Trading  Rico Müller	omerckel@mmwarburg.com +49 40 3282-2685	Designated Sponsoring Sebastian Schulz	mmagiera@mmwarburg.com +49 40 3282-2631
Sales Trading	rmueller@mmwarburg.com	Designated Sponsoring	sschulz@mmwarburg.com
Bastian Quast	+49 40 3282-2701	Jörg Treptow	+49 40 3282-2658
Sales Trading	bquast@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
MACRO RESEARCH Carsten Klude	+49 40 3282-2572	Dr. Christian Jasperneite	+49 40 3282-2439
Macro Research	cklude@mmwarburg.com	Investment Strategy	cjasperneite@mmwarburg.com
Our research can be t	found under:		
Warburg Research	research.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please conta	act:		
Andrea Schaper	+49 40 3282-2632	Kerstin Muthig	+49 40 3282-2703
Sales Assistance	aschaper@mmwarburg.com	Sales Assistance	kmuthig@mmwarburg.com